Abstract. The frequency of mass bee attacks has dramatically increased in the Americas following the introduction and spread of the aggressive Africanized 'killer' bee (Apis mellifera scutellata). As yet no specific therapy is available, which led us to develop an ovine Fab-based antivenom as a potential new treatment. Sera from sheep immunized against the venom contained high levels of specific antibodies, as demonstrated by ELISA and by small-scale affinity chromatography, against both whole (A. m. mellifera) venom and purified melittin. A nerve muscle preparation was used to show the myotoxic effects of the venom and neutralization by the antivenom. Antivenom neutralizing ability was also demonstrated using assays for venom phospholipase A 2 and in vivo activities. Venom from both European and Africanized bees appeared identical when analyzed by acid-urea gel electrophoresis. This antivenom may therefore provide the first specific therapy for the treatment of mass envenomation by either European or Africanized 'killer' bees.
The accidental introduction of the native African bee Apis mellifera scutellata into Brazil in 1957 and its subsequent displacement and hybridization of the long-established European bees A. m. mellifera and A. m. ligustica has resulted in the highly aggressive Africanized 'killer' bee. 1, 2 It is better adapted to warmer climates than its European counterparts and, as a result, has been highly successful and spread rapidly throughout Latin America. In 1992, the Africanized bee crossed the border into the United States and is now found in Texas, Arizona, New Mexico, and southern California. 3 It is predicted to eventually be distributed as far east as North Carolina. 2 These bees attack much more readily and in greater numbers than the European varieties, 1 and thousands of stings may be inflicted on a single individual. 4, 5 About 50 simultaneous stings can cause systemic envenoming and about 500 are probably necessary to cause death by direct toxicity, 4, [6] [7] [8] [9] [10] although one death in Arizona was due to only ϳ125 stings. 11 By 1985 , it was estimated that these bees had caused between 700 and 1,000 deaths, 12 and in Mexico there have been more than 190 such deaths between 1988 and 1993, with future estimates of 60 deaths per year. 13 Clinical features can include rhabdomyolysis, intravascular hemolysis, respiratory distress, hepatic dysfunction, hypertension, myocardial damage, shock, and/or renal failure. 4, 5, 8, 11 Each Africanized bee injects an average of 94 g of venom in less than a minute, compared with 147 g for the slightly larger European bee, and circulating venom levels in patients of up to 3.8 mg/L have been recorded. 4, 14, 15 The venom contains many biologically active components such as melittin, phospholipase A 2 , apamin, mast cell degranulating peptide, hyaluronidase, histamine, and dopamine. 16 Of these, melittin is predominant (ϳ50% by dry weight) and can disrupt cell membranes and produce pores even at low concentrations. 16, 17 Phospholipase A 2 enhances this membrane disruption by forming powerful membrane-active products, and these relatively nonspecific membrane effects are thought to be responsible for many of the clinical findings. [18] [19] [20] No specific therapy is available currently and a safe, effective treatment is urgently required. 4, 21 We describe here the preclinical development and assessment of a specific A. mellifera antivenom that will hopefully prove suitable for treatment of mass bee attacks.
MATERIALS AND METHODS
Bee venoms. Freeze-dried A. m. mellifera venom and its purified venom components were obtained from Latoxan (Rosans, France) and Africanized bee venom was obtained from Southwest Venoms (Tucson, AZ).
Antivenom. Antibodies were raised by immunizing nine, half-bred, Welsh ewes in groups of three with up to a maximum of either 0.25 mg, 1 mg, or 4 mg of A. m. mellifera venom every 28 days. Venom was dissolved in phosphatebuffered saline (1.3 ml/sheep) and mixed extensively with Brij 35 (0.2 ml/sheep) and Freund's adjuvant (3.25 ml/sheep) to form a stable water-in-oil emulsion. Freund's complete adjuvant was used for the primary immunization, and Freund's incomplete adjuvant was used for re-immunization at monthly intervals. The sheep were immunized intramuscularly in each forelimb and hindlimb and subcutaneously on either side of the neck. Ten-milliliter blood samples were collected from each sheep two weeks after each immunization, and once adequate antibody levels had been achieved, the sheep were bled (10 ml/kg of body weight). The serum was separated and passed through a 0.2-m filter and pooled prior to storage at Ϫ20ЊC. The IgG fraction was partially purified by precipitation with sodium sulfate (final concentration ϭ 18%) at 25ЊC for 15 min with mixing. The precipitate, after pelleting by centrifugation, was washed twice with 18% sodium sulfate, reconstituted in saline (0.9% NaCl), and the IgG was cleaved completely with papain to yield Fab fragments. 22 After dialysis against saline, Fab protein concentrations were determined by optical density measurements at 280 nm using an extinction coefficient of 1.4 for ovine Fab. Final antivenom concentrations were typically between 20 and 30 g/L.
Serum titer estimation. Serum antibody titers directed against purified melittin or whole venom were determined on the pooled monthly samples or bleeds by ELISA according to the method of Sjostrom and others. 23 Polystyrene microtiter plates (Nunc, Roskilde, Denmark) were coated with antigen (2 g/ml) and washed three times with ELISA wash buffer (137 mM NaCl, 2.68 mM KCl, 8.1 mM Na 2 HPO 4 , 0.25 mM thimerosal, 0.1% Tween 20) . Doubling dilutions of immune serum diluted with ELISA wash buffer were performed in duplicate. A reference antiserum (from a pool of sera with an established titer) and a normal sheep serum (NSS) control were included on each plate. Plates were incubated at 37ЊC for 1 hr, washed with ELISA wash buffer, and incubated with donkey anti-sheep IgG conjugated to horseradish peroxidase. Color development was achieved using 0.02% hydrogen peroxide and o-phenylenediamine dihydrochloride, stopped after 15 min with 3 M sulfuric acid, and read at 492 nm. Titers were determined at 50% of the background NSS corrected absorbance, and values were corrected for between assay variation using the reference antiserum.
Small-scale affinity purification. Cyanogen bromide-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) columns (1 g) were prepared according to the manufacturer's instructions, using either melittin or whole bee (A. m. mellifera) venom as the ligand at a concentration of 5 mg/g of dry gel. Loading and eluting conditions were optimized and conditions providing the highest levels of specific antibody with the lowest levels of nonspecific binding were chosen. Antiserum samples (500 l) were diluted in 0.9% saline/2% acetonitrile (6 ml), mixed for 18 hr with the gel at 4ЊC, washed (saline/2% acetonitrile), and eluted (100 mM glycine, pH 2.5). Specific antibody concentrations were determined based on their optical density at 280 nm, using an extinction coefficient of 1.5 for ovine IgG. Nonspecific binding was determined by running NSS and levels of specific antibody were corrected by subtracting the value due to nonspecific binding.
Phospholipase assay. Venom phospholipase A 2 activity was assessed by measuring the release of free fatty acids from a phospholipid substrate (phosphatidyl-choline, egg yolk type), using cresol red as a pH indicator. 24 Effects of various concentrations of A. m. mellifera venom were measured and the optimum concentration was used to assess antivenom neutralization. Venom (10 mg/L) was premixed with antivenom (non-affinity purified Fab) for 30 min at 37ЊC prior to substrate addition and the optical density at 573 nm was measured after 10 min.
Nerve-diaphragm assay. Left phrenic nerve-hemidiaphragm preparations were isolated from 20-35 g, male, outbred, white mice. 25, 26 Each was bathed in 60 ml of Krebs buffer (118 mM NaCl, 25 mM NaHCO 3 , 1.0 mM NaH 2 PO 4 .H 2 O, 4.8 mM KCl, 1.9 mM CaCl 2 .2H 2 O, 1.2 mM MgSO 4 .7H 2 O, 11.1 mM D-glucose) maintained at 32ЊC and supplied with 95% O 2 plus 5% CO 2 . Indirect stimulation (via the nerve) was applied at supramaximal voltage (ϳ3 V, 0.2 Hz, 0.2 msec) and muscle contractions were recorded using an isometric transducer linked to a Lectromed, Ltd. (Letchworth Garden City, United Kingdom) amplifier (HF cut 150 Hz) and chart recorder (MX216-100), using tissue holderelectrodes obtained from Harvard Apparatus, Ltd. (Edenbridge, United Kingdom). Indirect stimulation was continued for at least 30 min until a consistent twitch response was produced after which venom was added (t 0 ), and washed out after 30 min (t 30 ) and again after an additional 30 min (t 60 ). The decrease in contractions was calculated as a percentage of the contractions just before venom addition. The myotoxic effects of the venom were assessed by applying a short burst of direct (muscle) stimulation (0.2 Hz, 1 msec, ϳ 50 V) before venom addition and at 30-min intervals thereafter.
The ability of the high immunization dose group antivenom (non-affinity purified Fab) to neutralize the effects of the venom was assessed by premixing a fixed venom concentration (5 mg/L) with antivenom and incubating at 37ЊC for 30 min before addition to the hemidiaphragm preparation (t 0 ), followed by an identical dose cycle as outlined earlier.
Electron microscopy. Following the above experiment with a period of stimulation of 3.5 hr, control and venom treated (20 mg/L) diaphragm preparations were fixed and mounted using standard methods for transmission electron microscopy. Numerous sections were made from each preparation and photographs were taken that were representative of the entire tissue.
In vivo toxicity and neutralization. All solutions were sterile filtered (0.2 m) prior to use. The LD 50 of the venom (the amount that causes the death of 50% of the animals) was assessed by intravenous injection of various doses of venom in 0.2 ml of physiologic saline into the tail vein of 18-20 g male, out-bred, white mice. 27 Five mice were used for each venom dose and the LD 50 was calculated from the number of deaths within 24 hr. To assess antivenom (week 62 high dose immunization group, non-affinity purified Fab) potency, various amounts of antivenom were mixed with five times the LD 50 of venom; the mixture was then incubated at 37ЊC for 30 min and injected intravenously into mice. Five mice were used for each antivenom dose. The ED 50 of the antivenom (the amount that prevents 50% of the mice from dying) was calculated from the number of deaths within 24 hr after injection of the venom/antivenom mixture using probit analysis. 28 The maintenance and care of all experimental animals complied with British Home Office guidelines.
Venom analysis. Propionic acid-urea polyacrylamide (22%) gel electrophoresis was performed according to the method of Chettibi and Lawrence. 29 A conventional sodium dodecyl sulfate-polyacrylamide gel electrophoresis technique failed to separate the components.
RESULTS
The highest ELISA titers (up to 1:300,000 and 1:75,000) were produced against whole venom and melittin, respectively, when sheep were immunized with the largest dose schedule (up to 4 mg/sheep every 28 days). Specific antibody levels, as determined by small-scale affinity chromatography, also demonstrated that the high immunization dose produced the highest levels of specific antibodies (up to 8.8 and 4.5 g/L after subtracting the nonspecific binding) against whole venom and melittin, respectively (Figure 1) . Conversely, the lowest specific antibody levels were produced using the lowest immunization dose schedule (up to 0.25 mg/sheep every 28 days). A slow progressive increase in the antibody population that bound to melittin was noted in the sheep given the highest dose of venom without any sign of reaching a plateau after more than a year.
Neutralization of phospholipase A 2 activity was most pronounced using the high and medium immunization dose group antivenoms (Figure 2 ) with 400 mg/L of these able to fully neutralize 10 mg/L of venom phospholipase A 2 activity. From this data (50% neutralization) it was calculated that ϳ16 mg of antivenom would be required to neutralize the phospholipase A 2 activity of 1 mg of venom.
Electron microscopy revealed that the muscle fibers from FIGURE 1. Specific antibody levels, determined by small-scale affinity chromatography, directed against whole Apis mellifera mellifera venom (A) and against melittin (B) in the high (Ⅵ), medium (᭡), and low (᭢) immunization dose groups. a control diaphragm showed a normal characteristic banding pattern (Figure 3a) due to the presence of parallel myofibrils interspersed with mitochondria, sarcoplasmic reticulum, and triads. In contrast, muscle fibers from the venom-treated (20 mg/L) diaphragm showed complete disorganization of the normal architecture, with clumping of myofibrils and disruption of the sarcoplasmic reticulum and triads (Figure 3b ). These features were found across all the tissue sections taken from the diaphragm. This venom concentration also produced a parallel loss of the functional activity of the tissue.
An initial tonic contraction was produced both by the whole venom and by the purified melittin, followed by a progressive decrease in muscle contractions after their addition to the phrenic nerve diaphragm preparation. This decrease in muscle contraction showed a similar time course whether the preparation was stimulated indirectly via the nerve or directly via the muscle with a range of venom concentrations (2-20 mg/L). This indicates a direct myotoxic effect and no neurotoxic activity could be demonstrated. The progression of the toxicity appeared unaffected by two washes of the tissue with Krebs buffer, and use of a venom concentration of 20 mg/L showed that muscle contractions had virtually stopped after 150 min. Increasing antivenom concentrations had a progressive neutralizing effect, but even a high antivenom concentration (800 mg/L) could not completely neutralize the toxicity of the venom (Figure 4) . The A. m. mellifera venom had an LD 50 of 3.1 mg/kg and mice receiving high venom concentrations often had immediate convulsions leading to death within minutes. The ED 50 for the antivenom preparation was 258 mg/kg (95% confidence limits from probit analysis ϭ 237-274) against 5 times the LD 50 . From this data, it can be calculated that ϳ20.5 mg of antivenom is required to neutralize each milligram of venom.
The venom was clearly separated into its individual components by an acid urea gel system, and these components were identified by running the purified major components: melittin, phospholipase A 2 , mast cell degranulating peptide, and apamin. No differences between the European or Africanized bee venoms could be detected ( Figure 5 ).
DISCUSSION
The frequency of mass bee attacks has dramatically increased in the Americas following the introduction and spread of the aggressive Africanized killer bee. As yet, no specific therapy is available for these toxic effects, 4,21 which led us to develop an ovine antibody fragment (Fab)-based antivenom as a potential new treatment.
In our laboratory, total IgG levels of 28 g/L were found in pooled antisera from sheep, and others have reported levels in NSS greater than 26 g/L. 30 These high levels of IgG may explain why sheep often produce relatively high levels of specific antibodies (e.g., 7-15 g/L) to an immunogen. 31 The size of sheep also helps ensure their suitability for scaling-up the procedure to produce antivenoms commercially. 32, 33 Levels of the venom-specific antibodies were consis- tently greater using the highest immunogen concentration (4 mg/sheep), so that the optimum immunization dose may not have been reached.
The present results indicate that early in the immunization schedule most of the specific antibodies were directed against venom components other than melittin. Phospholipase A 2 is one of the most immunogenic components of bee venom and may contribute to the generalized toxicity of envenomation by a synergistic interaction with melittin. 3, [18] [19] [20] [21] 34 The antivenoms raised by immunizing with 1 or 4 mg of venom fully neutralized this important enzymatic activity. Melittin is also important, with its insertion into cell membranes being thought to cause disruption of the surrounding phospholipid bilayer, which allows phospholipase A 2 to gain access to its phospholipid substrate. 35 However, melittin is said to be poorly immunogenic probably because of its small size (26 amino acids with a molecular weight of 2,800 Da) and strongly hydrophobic regions. 3, 21, 34 It forms the major venom component and, fortunately, up to 4.5 g/L of specific antibodies to this peptide could be generated in sheep provided the period of immunization was sufficiently prolonged. The effects of the venom on the phrenic nerve diaphragm preparation were of a predominantly myotoxic type, as shown by both ultrastructural and functional changes. It produced an immediate tonic contraction, similar to the cardiotoxins, 36 which appears to be produced by the melittin. The antivenom was capable of neutralizing both the myotoxic effects and the initial tonic contraction.
The LD 50 of A. m. mellifera venom in this study was similar to that previously reported for both European and Africanized bee venoms. 14, 21, 37 The dramatic manifestations and rapid lethal effects produced by high venom concentrations in mice are probably due to apamin, which acts on the central nervous system. 16, [38] [39] [40] [41] The antivenom was capable of neutralizing the venom in vivo when assessed using the standard efficacy (ED 50 ) test, and it was calculated that ϳ20.5 mg of antivenom was required to neutralize each milligram of venom. The ED 50 results indicate, indirectly, that the antivenom is also effective against apamin.
Previous ED 50 studies have demonstrated that ϳ one-third less Fab by weight compared with IgG was required to neutralize a set quantity of snake venom, presumably due to the removal of the Fc fragment (Sjostrom LI, 1994 , A Comparison of Some European Viper Venoms and Antivenoms. PhD thesis, University of London, London, United Kingdom). A Fab-based antivenom was chosen for this study because it has long been recognized that giving an antivenom with the Fc region intact (e.g., whole IgG) is more likely to produce side effects then antibody fragments (e.g., Fab, F(abЈ) 2 ). [42] [43] [44] The Fab fragments are also able to quickly penetrate the interstitial space and have a greater volume of distribution than intact IgG. 45 Venom from European and Africanized bees appeared identical when resolved by a sensitive electrophoresis system using differences in both the charge and size of the components. Based on this finding and their similar toxic properties and cross-reactivity, 14, 21, 37, 46 it is probable that the antivenom raised against the European bee venom will be equally effective at neutralizing the venom of the Africanized bee.
The majority of bee sting reactions involve just a single sting and are severe only in the 0.15-4.0% of people with true systemic hypersensitivity to hymenoptera venoms. 47 These allergic-type individuals are at a high risk of developing life threatening IgE-mediated or anaphylactoid reactions, which must be treated conventionally, (e.g. antihistamines, steroids, alpha/beta agonists, bronchodilators, and adrenaline). 48 In the United States, some 40 deaths per year result from such a reaction and it usually occurs within 1 hr. 47 Such subjects will not benefit from the availability of an antivenom whose use will be limited to those stung by 50 or more bees who often develop features of systemic toxicity many hours later, with the majority of deaths only after ϳ22 hr. 4, 11 This suggests that the use of antivenom may still be beneficial even if delayed many hours. This is supported by the benefits that may arise by receiving antivenom several days after snake envenoming. 32, 49 Clinical studies are now essential to assess the effectiveness of this antivenom in neutralizing the high systemic levels of venom found after mass bee attacks and, thereby, hopefully alleviate the clinical manifestations and improve the prognosis. Unlike with snake bites in which the amount of venom injected may vary greatly (e.g., 0-1.5 g) 50 and is unknown, the ability to assess the amount of bee venom injected after a mass attack by counting the number of stings should, theoretically, be of help in evaluating whether 1) antivenom is required (e.g., Ͼ 50 stings) and 2) the quantity of antivenom required. Again, clinical trials will be necessary to assess this. In conclusion, this study has demonstrated that a specific A. mellifera antivenom can be raised in sheep that will neutralize the toxic components of the venom.
